SABS Past Earnings image   This SABS past earnings page last updated 11/16/2022
SABS Past Earnings
PeriodPast Earnings DateGAAP
Q3 202211/15/2022-0.160
Q2 20228/10/2022-0.110
Q1 20225/12/20220.020
SABS Past Revenue
PeriodPast Earnings DateGAAP
Q3 202211/15/20220.00B
Q2 20228/10/20220.01B
Q1 20225/12/20220.01B
Quotes delayed 20 minutes

Email EnvelopeFree SABS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
SAB Biotherapeutics (SABS) is categorized under the Miscellaneous sector; to help you further research past earnings across stocks, below are some other companies in the same sector:

SBBP Past Earnings
SEAT Past Earnings
SES Past Earnings
SHCR Past Earnings
SHPW Past Earnings
SKIL Past Earnings
SLDP Past Earnings
SLGC Past Earnings
SMFR Past Earnings
SMR Past Earnings

SABS Past Earnings Q&A

What was the best and worst SABS past earnings results?
For SAB Biotherapeutics, I'm wondering what the company's very best and worst earnings results have been, on an earnings per share basis?

✔️Accepted answer: The highest SABS past earnings result in our data set was 0.020/share posted in Q1 2022, while the lowest was in Q3 2022 when SABS posted -0.160/share.

  Suggested answer: The biggest top line earnings performance — aka revenue — quarter was in Q1 2022 when SABS reported 0.01B in revenue, while the quarter with the lowest revenue in our data set was Q3 2022 at 0.00B of revenue.

  Suggested answer: There are 3 SABS past earnings results in our data set.

On this page we presented the SABS past earnings date information for SAB Biotherapeutics. Reviewing that SABS Past Earnings for the company, we see that the highest past earnings result in our data set was in Q1 2022, when SABS posted gaap of 0.020/share. Meanwhile the lowest SABS past earnings result was in Q3 2022, when SABS posted gaap of -0.160/share. Turning to top line revenue performance, the biggest revenue quarter in our data set was seen in Q1 2022 when SABS reported 0.01B in revenue, while the smallest revenue quarter was Q3 2022 when SABS reported 0.00B in revenue.

Any self directed investor doing their due diligence on SABS or any other given stock can benefit from researching all of the SAB Biotherapeutics past earnings — and here, we present each quarter's result all together on one page for easy comparison. Studying this information can help when projecting future earnings, as well as determining whether the past earnings trajectory justifies the current stock value. That's why we bring you PastEarnings.com to make it easy for investors to investigate SAB Biotherapeutics past earnings, or the past earnings information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for SABS. Thanks for visiting, and the next time you need to research SABS past earnings or those of another stock, we hope you'll think of our site, as your go-to past earnings research resource of choice.

Recommended: OUST shares outstanding history, Institutional Holders of MCRS, Top Ten Hedge Funds Holding DBO.

 

SABS Past Earnings | www.PastEarnings.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in PastEarnings.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.